Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Antiviral Agents / pharmacology
-
Betacoronavirus / physiology*
-
COVID-19
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / pathology
-
Coronavirus Infections / virology
-
Humans
-
Immune Evasion
-
Interferon Lambda
-
Interferon Type I / genetics
-
Interferon Type I / immunology*
-
Interferon Type I / pharmacology
-
Interferons / genetics
-
Interferons / immunology*
-
Interferons / pharmacology
-
Pandemics
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / pathology
-
Pneumonia, Viral / virology
-
Recombinant Proteins / pharmacology
-
SARS-CoV-2
-
Signal Transduction
Substances
-
Antiviral Agents
-
Interferon Type I
-
Recombinant Proteins
-
Interferons
-
Interferon Lambda